Quarterly ResultJul 30, 2026, 04:09 PM
CareDx Q2 Revenue +52% to $132M; Raises FY26 Guidance
AI Summary
CareDx, Inc. reported strong second-quarter 2026 financial results, with revenue increasing 52% year-over-year to $132 million and GAAP net income reaching $111 million. The company also significantly raised its full-year 2026 revenue guidance to $490 million-$500 million and Adjusted EBITDA guidance to $66 million-$78 million. These results follow the divestiture of its Lab Products business, which generated a $113 million gain, and the acquisition of Naveris, strengthening its focus on precision medicine diagnostics.
Key Highlights
- Q2 2026 revenue increased 52% year-over-year to $132 million.
- GAAP net income for Q2 2026 was $111 million, compared to a $9 million loss in Q2 2025.
- Adjusted EBITDA for Q2 2026 rose to $25 million from $5 million in Q2 2025.
- Full-year 2026 revenue guidance raised to $490 million-$500 million.
- Full-year 2026 Adjusted EBITDA guidance raised to $66 million-$78 million.
- Completed divestiture of Lab Products business, recognizing a $113 million gain.
- Completed acquisition of Naveris, enhancing precision diagnostics focus.
- CMS finalized Medicare coverage for AlloSure® and AlloMap® tests.
Price Impact
More from CDNA